Skip to content

Insider · CIK 0002109144

Beth Grous

officer

Files at GENB (Generate Biomedicines, Inc.). First filing Mar 2, 2026, latest Mar 2, 2026.

In brief

Beth Grous files SEC Form 4 as officer at GENB (Generate Biomedicines, Inc.). Since Mar 2, 2026, Beth Grous has reported 1 open-market buy worth $4,800 and 0 open-market sells worth $0, the latest filed on Mar 2, 2026.

A track record needs three past buys with six months of prices behind them; Beth Grous has 0, so none is measured yet.

The newest scored trade: bought $4,800 of GENB on Mar 2, 2026, filed Mar 2, 2026, scored 48 (moderate). In the last 12 months: 1 buy worth $4,800 and 0 sells worth $0.

Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
1 / 0
$4,800 bought, $0 sold

Where the trades landed

Last year at the company this insider has traded most, with each buy and sell on the bar it happened.

GENB: Generate Biomedicines, Inc.

GENBOct 9, 2026 · close 14.34

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

This insider’s open-market buys and sells, scored.

ScoreCompanyValueHoldingsPrice contextFiled
48Moderate
GENBbuy 5
Generate Biomedicines, Inc.
$4,800
300 shares
-0% from low-4% from high

Transactions

Every row this insider has filed, 2 in all, newest first.

DateCompanyTransactionSharesPriceValueHoldings afterFiled
Mar 2, 2026GENB
Generate Biomedicines, Inc.
POpen-market purchase
Common Stockindirect: By Spouse
+300$16.00$4,800300Mar 2, 2026
Feb 26, 2026GENB
Generate Biomedicines, Inc.
AGrant or award
Stock Option (Right to Buy)derivative
+114,020$0.00$0114,020Mar 2, 2026

Questions about Beth Grous

Answered from the filings on this page, as of the latest one.

Is Beth Grous buying or selling?

In the last 12 months Beth Grous reported 1 open-market buy worth $4,800 and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $4,800 of GENB on Mar 2, 2026. Grants, option exercises and tax withholding are not counted.

How did Beth Grous's past buys perform?

Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Beth Grous has 0.

Where does Beth Grous file Form 4?

Beth Grous has filed Form 4 at GENB (Generate Biomedicines, Inc.) as Chief People Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Beth Grous: insider trades and track record | InsiderTell